High plasma level of long Pentraxin 3 is associated with insulin resistance in women with polycystic ovary syndrome

Gynecological Endocrinology

Volumn 28, Issue 9, 2012, Pages 722-725

  Aydogdu, Aydogan ^a   Tasci, Ilker ^a   Tapan, Serkan ^a   Basaran, Yalcin ^a   Aydogan, Umit ^a   Meric, Coskun ^a   Sonmez, Alper ^a   Aydogdu, Sebnem ^b   Akbulut, Halil ^a   Taslipinar, Abdullah ^a   Uckaya, Gokhan ^a   Azal, Omer ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b ANKARA MEVKI MILITARY HOSPITAL   (Turkey)

Author keywords

Inflammation; Insulin resistance; Long Pentraxin 3; Polycystic ovary syndrome

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PENTRAXIN 3; TESTOSTERONE;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL; WAIST HIP RATIO;

ADOLESCENT; ADULT; BLOOD GLUCOSE; BODY MASS INDEX; C-REACTIVE PROTEIN; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INSULIN; INSULIN RESISTANCE; OBESITY; POLYCYSTIC OVARY SYNDROME; SERUM AMYLOID P-COMPONENT; WAIST-HIP RATIO;

EID: 84865331480     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2011.652719     Document Type: Article

References (30)

1. Galluzzo A, Amato MC, Giordano C. Insulin resistance and polycystic ovary syndrome. Nutr Metab Cardiovasc Dis 2008;18:511-518.
2. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004;59:141-154. (Pubitemid 38140845)
3. Sathyapalan T, Atkin SL. Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. Mediators Inflamm 2010;2010:758656.
4. Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, Blumenfeld Z. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004;89:2160-2165. (Pubitemid 38619847)
5. Bloomgarden ZT. Inflammation and insulin resistance. Diabetes Care 2003;26:1922-1926. (Pubitemid 36929145)
6. Andersson CX, Gustafson B, Hammarstedt A, Hedjazifar S, Smith U. Inflamed adipose tissue, insulin resistance and vascular injury. Diabetes Metab Res Rev 2008;24:595-603.
7. Bottazzi B, Vouret-Craviari V, Bastone A, De Gioia L, Matteucci C, Peri G, Spreafico F, et al. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem 1997;272:32817-32823. (Pubitemid 28023616)
8. Lee DH, Jeon HK, You JH, Park MY, Lee SJ, Kim SS, Shim BJ, et al. Pentraxin 3 as a novel marker predicting congestive heart failure in subjects with acute coronary syndrome. Korean Circ J 2010;40:370-376.
9. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005;23:337-366. (Pubitemid 40563173)
10. Alberti L, Gilardini L, Zulian A, Micheletto G, Peri G, Doni A, Mantovani A, Invitti C. Expression of long pentraxin PTX3 in human adipose tissue and its relation with cardiovascular risk factors. Atherosclerosis 2009;202:455-460.
11. Salustri A, Garlanda C, Hirsch E, De Acetis M, Maccagno A, Bottazzi B, Doni A, et al. PTX3 plays a key role in the organization of the cumulus oophorus extracellular matrix and in in vivo fertilization. Development 2004;131:1577-1586. (Pubitemid 38559284)
12. Suliman ME, Yilmaz MI, Carrero JJ, Qureshi AR, Saglam M, Ipcioglu OM, Yenicesu M, et al. Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease. Clin J Am Soc Nephrol 2008;3:976-985.
13. Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81:19-25.
14. Cho LW, Randeva HS, Atkin SL. Cardiometabolic aspects of polycystic ovarian syndrome. Vasc Health Risk Manag 2007;3:55-63. (Pubitemid 46860716)
15. Kirschner MA, Samojlik E, Drejka M, Szmal E, Schneider G, Ertel N. Androgen-estrogen metabolism in women with upper body versus lower body obesity. J Clin Endocrinol Metab 1990;70:473-479.
16. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE, Kuller LH. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000;20: 2414-2421.
17. Hu W, Qiao J, Yang Y, Wang L, Li R. Elevated C-reactive protein and monocyte chemoattractant protein-1 in patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2011;157:53-56.
18. González F, Rote NS, Minium J, Kirwan JP. Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metab Clin Exp 2009;58:954-962.
19. Sayin NC, G?cer F, Balkanli-Kaplan P, Y?ce MA, Ciftci S, K?c?k M, Yardim T. Elevated serum TNF-α levels in normal-weight women with polycystic ovaries or the polycystic ovary syndrome. J Reprod Med 2003;48:165-170. (Pubitemid 36368954)
20. Kolbus A, Walch K, Nagele F, Wenzl R, Unfried G, Huber JC. Interleukin-1 α but not interleukin-1 β gene polymorphism is associated with polycystic ovary syndrome. J Reprod Immunol 2007;73:188-193. (Pubitemid 46402937)
21. Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring A, Hutchinson WL, Pepys MB. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-242. (Pubitemid 29056365)
22. Steel DM, Whitehead AS. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 1994;15:81-88. (Pubitemid 24049801)
23. Savchenko A, Imamura M, Ohashi R, Jiang S, Kawasaki T, Hasegawa G, Emura I, et al. Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 2008;215:48-55. (Pubitemid 351619875)
24. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, Sagara M, Kubota I. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008;155:75-81. (Pubitemid 350234768)
25. Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, Pizzetti F, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000;102:636-641. (Pubitemid 30640663)
26. Kotooka N, Inoue T, Aoki S, Anan M, Komoda H, Node K. Prognostic value of pentraxin 3 in patients with chronic heart failure. Int J Cardiol 2008;130:19-22.
27. Liu S, Navarro G, Mauvais-Jarvis F. Androgen excess produces systemic oxidative stress and predisposes to β-cell failure in female mice. PLoS One 2010;5:e11302.
28. Holmäng A, Svedberg J, Jennische E, Björntorp P. Effects of testosterone on muscle insulin sensitivity and morphology in female rats. Am J Physiol 1990;259:E555-E560. (Pubitemid 20340374)
29. O'Meara NM, Blackman JD, Ehrmann DA, Barnes RB, Jaspan JB, Rosenfield RL, Polonsky KS. Defects in β-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993;76:1241-1247. (Pubitemid 23155443)
30. Dunaif A, Finegood DT. β-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:942-947. (Pubitemid 26083951)